List of Biotech, Pharmaceutical & Life Sciences companies in Oregon - 51

13therapeutics is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. The company has an innovative platform for discovering and enhancing peptides, derived from naturally occurring pathogens (e.g., bacteria, viruses, fungi), which modulate the human immune response. This platform has produced a portfolio of peptides with demonstrated immune-regulatory activity and with varying mechanisms of action. These peptides have potential application for treatment of both acute and chronic inflammatory diseases. Many of the company’s peptides are capable of multiple methods of delivery, have shown serum stability, and have other desired features clinical therapeutics. Target conditions include the treatment of acute inflammatory diseases such as Acute Otitis Media (AOM), Systemic Inflammation, Meningitis, Traumatic Brain Injury (TBI), Uveitis and Ischemia. We are also evaluating peptides in chronic models for Lupus, Rheumatoid Arthritis (RA), Multiple Sclerosis, Atherosclerosis, Crohn’s Disease and Psoriasis, among others. Using our evolution-based methodology, we envision rapid development across several disease states.

AgonOx, Inc.is a spin-off company from the Providence Cancer Center located in Portland, Oregon. We are developing immune system activators for use in cancer therapy. Research in the field of T-cell modulation conducted worldwide with OX40 and other agents has demonstrated that the use of T-cell modulating therapies in combination with specific anti-tumor therapies have the potential for yielding therapeutic benefits for patients with cancer. AgonOx is focused on the development of immune system modulators in combination with other promising agents in the immune oncology space.

Blending technology and science, we develop instrumentation to improve outcomes. Araceli Biosciences delivers high-performance scientific tools for tissue and cell-based biomarker discovery, drug discovery and drug development. With decades of combined biomedical research and instrument design experience, we are focused on developing scientific instrumentation to improve outcomes and enable our customers to advance scientific and medical research. Speed is essential for furthering our understanding of biology, and we believe in reducing the time needed to acquire high-quality data and obtain clear, high-quality results. By making advanced technologies accessible, we allow researchers to focus on the science, not the tool. Our goal is to develop innovative products that accelerate basic research, drug discovery, and manufacturing to advance healthy outcomes. We believe in blurring the line between science and technology, using one to improve the other in a holistic approach. We strive to make the drug discovery process more efficient, reducing the time and bandwidth needed to screen compounds. By pairing fast, easy to use hardware with advanced artificial intelligence analysis algorithms, we aim to transform the drug discovery pipeline, allowing customers to fail faster.

Aronora is a translational biotechnology company (aronorabio.com) engaged in the development of proprietary biologic therapeutics, including recombinant monolconal antibodies and enzymes. Rational design of our innovative therapeutic agents is expected to result in drug products that reduce the progression and growth of life-threatening blood clots without the detrimental bleeding side effects that characterize all currently marketed antithrombotic drugs. Our products are intended to be used in difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases.

Every new drug has challenges to overcome on its journey from discovery to market. With today's more specific targets and more challenging chemical spaces, drug delivery and development often requires an enabling technology. We provide a collaborative R&D approach, specializing in particle engineering, drug delivery, drug development and manufacturing expertise to the pharmaceutical industry. We want to partner with you on your challenging molecule and help bring it to market. How can we help?

At BIOMOTUM, we envision a world where all people have access to optimal mobility. Our mission is to optimize human mobility by providing intelligent and intuitive wearable systems, to a wide range of users in the medical and consumer markets. We empower individuals to live healthy and productive lives through the use of our clinically validated products. The Problem A person's ability to engage in physical activity, including activities of daily living, is essential to their health, independence, and general wellbeing. According to the CDC, approximately 50 million U.S. adults and children have a physical disability and are unable to engage in some activities of daily living or achieve a sufficient amount of physical activity. Mobility training is critical to improving mobility but there is currently no viable way to deliver a sufficient dose of active gait training. Our Solution The BIOMOTUM System addresses the need for individuals to be mobile while being able to engage in sufficient mobility therapy. It allows them to walk independently in the clinic, at home and in the community. Clinical trials have repeatedly demonstrated improvement in mobility outcomes in children with CP. As a smart device, it provides rehabilitation professionals and users activity data to facilitate progression and continued improvement in mobility. Our History BIOMOTUM was founded in 2019, by Dr. Zach Lerner, Dr. Ray Browning and Joe Lerner. The founders have been associates for many years. Drs. Lerner and Browning met in 2011 through a shared interest pediatric physical activity as a way to improve chronic diseases and have maintained collaborations since that time.

Birch Biosciences uses Artificial Intelligence, bioinformatics, and high-throughput screening techniques to effectively engineer enzymes for recycling plastic.

BSK Associates (BSK) provides consulting engineering and testing for clients with projects ranging in size from small to complex, in both natural and built environments. Celebrating over 49 years, BSK is employee-owned, and has grown to a staff of nearly 200 with offices, laboratories, and sample drop-off locations throughout Northern and Central California. Since 1966, BSK has been closely involved with the earth sciences and construction materials. We apply this knowledge and experience to meet the needs of client industries including agriculture, commercial/retail, education, energy, healthcare, aggregate/mining, transportation, manufacturing, water, telecommunications, and local, state and federal agencies.

Gust is the global SaaS platform for founding, operating, and investing in scalable, high-growth companies. Gust’s online tools help entrepreneurs start, run, and fundraise for companies and provide deal flow and relationship management for investors. As the world’s largest community of entrepreneurs and early-stage investors from 191 countries, Gust pioneered the equity funding collaboration industry and is the official platform of the world’s leading angel investor federations and venture accelerators. More than 500,000 startups have already used Gust to connect with over 70,000 investment professionals. Gust powers the official online hubs of the world’s largest innovation ecosystems including New York City (Digital.NYC), Boston (StartHub.org) and London (Tech.London).

Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management. Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Türkiye resulting in rapid patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials. We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data. Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.

Enosi Therapeutics is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases ( Lasker Award, 2003 ); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins ( Lasker award, 2019). Enosi Therapeutics combines Feldmann and Shepard’s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody’s unique combination of medical, scientific and management expertise to expand therapeutic options.

Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. Since 1987, Eurofins has grown from one laboratory in Nantes, France to ca. 62,000 staff across a network of independent companies in 62 countries, operating over 900 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Floragenex is an biotechnology company that provides innovative solutions for genomic analysis in human, plant and animal systems. With multiple offices located on the US Pacific coast, our technologies allow investigation of genomes at unprecedented levels for academic, governmental and commercial researchers worldwide.

Founded in 1993, Flora Research Laboratories, LLC focused intensely on the authentication of natural plant derived essential oilsin the aromatherapy, flavor and fragrance industry.Founded in 1993, Flora Research Laboratories, LLC focused intensely on the authentication of natural plant derived essential oilsin the aromatherapy, flavor and fragrance industry.

Grace Bio-Labs manufactures products for life science research and molecular diagnostics. Our chambers and seals offer rapid setup for containment of samples for staining, imaging, incubation, hybridization, and enzymatic reactions. Sealed chambers of various dimensions offer significant advantages over standard coverslip incubation, and can minimize precious reagent use during assays. Applications for these chambers include proteomic, genomic, tissue and cell analysis. Our portfolio of protein microarray products, including ONCYTE® nitrocellulose film slides and complemenatry reagents for protein microarrays , are designed to work together to provide the highest sensitivity and quantification for protein diagnostics and proteomic studies.

Founded in 2008, TraceGains connects people and information so teams can work smarter. As a global technology company, we provide networked innovation, quality, and compliance solutions to consumer brands that want to reduce supply chain risk, speed up business processes, and take control of data. On average, companies find 80% of their suppliers already on TraceGains Network, allowing them to connect and collaborate instantly. With TraceGains companies can: Innovate Faster: Accelerate time to market with increased efficiency and speed at every stage of product development. Increase Insight: Achieve complete line of sight into operations, suppliers, and product development processes. Work Smarter: Digitize and standardize all quality and compliance documentation in one platform, accessible from anywhere. TraceGains was recently named "Best in Category" for Food Safety Management by FeaturedCustomers. FeaturedCustomers honored TraceGains because TraceGains has the most positive customer reviews in the industry. TraceGains is the winner of the Stratus Award for Cloud Collaboration. The company was also among the Food Logistics Top 100 software and technology providers and was named a Top 20 Information Technology Firm by ColoradoBIZ magazine. Learn more about TraceGains products at www.tracegains.com. Follow TraceGains on Twitter and Instagram: @TraceGains.

HTI accelerates drug discovery for Biotech and Pharma companies by providing structure determination services using cryogenic-electron microscopy (cryo-EM) and machine learning based image processing software. As a member of the Oregon Bioscience Incubator, HTI is partnering with leading research institutions and cryo-EM centers.

Meet IFF: We boldly bring together science and creativity to create what the world needs. An industry leader in food, beverage, scent, health and biosciences, we create essential solutions – from global icons to unexpected innovations and experiences. Equal parts outspoken and analytical, our international collective of thinkers works with customers to bring scents, tastes, experiences, ingredients and solutions for products people crave. With 22,000 employees across 65 countries, more than 110 manufacturing facilities, 100 R&D centers, and 33,000 customers across the world, we're poised to make a difference on an unprecedented scale. Without our boundary-pushing passion and end-to-end expertise, the future wouldn't be the same. Visit us at www.iff.com to learn more about how our talented people and new technology are challenging the expected, championing creators and doing more good for people and planet. Explore what sets us apart.

Hemex Health focuses on commercializing proven research into cost-effective, intuitive devices optimized to make diagnostics more accessible at the front lines of healthcare. Our products are designed to be easy to use and provide benefit quickly and effectively for the healthcare worker and patient on the ground, at the point-of-need. The company's leaders, with backgrounds in international business and biomedical engineering, have decades of success in developing and delivering more than 60 products that have made a difference in people's lives. We leverage our experience in building successful medical products to solve major needs in global health. Our low-cost technologies are targeted for the developing world and can impact millions by identifying diseases which can be affordably treated. Hemex is developing a diagnostic platform (utilizing technology which received a 2016 Patents for Humanity Award) that can quickly and easily diagnose hemoglobin disorders, such as sickle cell disease and beta thalassemia, from a drop of blood. The solution provides point-of-care access to diagnostic information faster, more cost-effectively, and more accurately than any solution on the market today. Hemex is an equal opportunity employer. All employment-related decisions are based solely upon one's individual merit and qualifications directly related to professional competence, and without regard to race, color, religion, national origin, pregnancy status, sex (gender}, age, marital status, mental or physical disability, sexual orientation, gender identity, military or veteran status, genetic history, or any other characteristic or classification protected by applicable law. We will also attempt to reasonably accommodate an individual based on his/her physical or mental limitation or because of the individual's sincerely held religious beliefs.

Madorra is empowering women to live fuller, richer, healthier lives. Our first product is changing the paradigm for treating vaginal dryness by providing a medical device solution to a problem that has previously only been served by pharmaceuticals. We're giving postmenopausal women and breast cancer survivors the power to choose the non-hormonal treatment option they want. Madorra has developed the first, non-invasive, non-hormonal medical device to treat vaginal atrophy. This is an easy-to-use, at-home device, providing both immediate and long-term benefits.

Micro Systems Engineering, Inc. (MSEI), with its main office in Lake Oswego, Oregon, is is a pioneer in developing innovative implantable medical device technologies and devices that save and enhance the quality of life for millions of patients across the globe. With more than 40 years of experience in design and manufacturing active implantable medical devices, our continuing success is based on our company's core values – innovation, quality, reliability, integrity, teamwork, and undisputed expertise – thus enabling us to inspire confidence and trust in physicians and patients worldwide. MSEI has two main divisions, Operations and System Design & Development. With over 400 technical staff including physicists, electrical, software, biomedical and materials engineers, MSEI employs an elite team of the brightest minds in the medical technology industry. The Operations division is a specialist in medical microelectronics manufacturing including development, design, testing, supply chain and system integration for medical technology, in particular for active implants in the area of CRM (cardiac rhythm management) and other medical applications. The Operations division is dedicated to the innovative design and quality construction of electronic modules used in implantable medical devices. System Design & Development is the innovation center for next generation class III active implants. This includes full system design, clinical research, hardware and software, as well as the design and test of application-specific integrated circuits (ASICs). The resulting products deliver life-saving therapies to patients accurately and reliably across the globe.

Since 1926, Monrovia has selected and grown the healthiest, highest quality, and best performing plants for your landscape. Our Craftsmen put their hearts, minds, and hands into ensuring the lasting beauty of our plants and your garden. Be inspired to grow beautifully, grow confidently, and grow responsibly with Monrovia.

As the world’s leading manufacturer and supplier of mycorrhizal soil inoculants, Mycorrhizal Applications is dedicated to sustainability by providing the agriculture, horticulture, landscaping, turf, and forestry industries with efficient and effective microbial-based biorational solutions. Mycorrhizal Applications researches and manufactures beneficial mycorrhizal fungi that greatly accelerate plant growth by increasing the surface absorbing area of roots as much as 50 times. This symbiotic fungus produces a healthier root system which requires fewer inputs such as nutrients and water and leads to optimal soil health, higher yields, increased plant stress resilience, and crop sustainability. Mission: At Mycorrhizal Applications, we harness the power and wisdom of natural systems to promote living soils and increase quality, productivity, and health in all industries involving soils, plants, and people. Visit our Careers Page for more info, and to view our current career opportunities: https://mycorrhizae.com/careers/

Najít Technologies is dedicated to the development of safe and effective vaccines against infectious diseases of global importance.

NeuraMedica is medical device startup focused on the development of a novel, bioabsorbable surgical clip for durotomy closure in spinal surgery. This technology was intially developed out of Oregon Health and Science University (OHSU). The company is located in Oregon City, Oregon in the Portland Metropolitan area.

North American Plants, INC offers high-quality starts of desirable shade trees, shrubs, vines, rootstocks and nut and berry varieties, all propagated in tissue culture.

OMICS USA is an independent laboratory that offers testing services for allergens, chemical Residue, DNA/GMO, FDA Import Detention Testing, food safety, inspection services, microbiology, mycotoxins, nutrition, US EPA GLP (Good Laboratory Practices)

The Oregon Bioscience Incubator (OBI), formerly known as the Oregon Translational Research and Development Institute (OTRADI), is a 501(c)(3) non-profit research and economic development institute whose mission is to accelerate bioscience industry growth and job creation for the state of Oregon. OBI is committed to economic development, startup business incubation, and broad-based scientific and entrepreneurial mentoring, with the goal of spurring development and translation of innovative research into products and companies that benefit human health. In 2013, OBI opened Oregon's first and only bioscience-focused business incubator--the OTRADI Bioscience Incubator. Since opening, the Oregon Bioscience Incubator has grown from six to twenty-nine startup companies.

Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research.OHSU's singular focus on improving health starts with Oregonians and has global impact. They are the only academic health center in Oregon, but they are also nationally distinct as a university dedicated solely to advancing health sciences. This allows them to concentrate resources on research to prevent and cure disease, on education that prepares physicians, dentists, nurses and other health professionals to succeed in an evolving health care environment, and on patient care that incorporates the latest knowledge and discoveries.Based in Portland, they have 16,000 employees, operate the top-ranked adult and children's hospitals in Oregon, and secure competitive research funding of more than $400 million a year. As a public organization, they provide community outreach and services for Oregon's most vulnerable populations.

Oregon State University continues to advance its 150-year mission to provide access to a high-quality education as Oregon's largest and only statewide public research university.

Opening Eyes Beautifully!! Osheru is dedicated to leading minimally invasive technology for excess skin removal. Ziplyft, our innovative device, streamlines eyelid surgery for patients and surgeons, while expanding the market for this procedure.

PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company. We develop novel combination and immunotherapies to treat cancer by bringing complementary biological pathways together to achieve synergistic clinical benefit. Our therapeutic candidates bridge the innate and adaptive immune systems by generating profound CD8+ T cell production. Our pipelines are patented AIRISE (Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors) and ARAC (Antigen Release Agent and Checkpoint Inhibitor) pipelines that generate anti-tumor immunity when given locally (AIRISE) or systemically (ARAC) by relying on patient' s own tumor in situ as the source of antigens.

Penderia Technologies develops wireless technologies for orthopedic applications, with a focus on implantable sensors for monitoring injury and healing progress.

Phylos is a cannabis genetics company focused on helping growers of all sizes to succeed commercially with seeds that produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seeds that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary technologies and its cultivation, extraction, and formulation expertise to provide partners with unparalleled THCV genetics and natural, safe and effective ingredients.

We sequence whole plasmids, amplicons, whole bacterial genomes, and colonies overnight, without the need for primers and minipreps. Plasmidsaurus is on a mission to accelerate new cures and promote a healthier planet by unlocking new levels of productivity in scientists using DNA tools to bring their ideas to life. The company’s DNA sequencing services are used daily by thousands of innovators, including Nobel prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries.

Providence Health & Services in Oregon is a not-for-profit Catholic network of hospitals, care centers, health plans, physicians, clinics, home health care and affiliated services.

RevMedx is a start-up medical device company dedicated to bringing lifesaving products to the field of trauma medicine. Working under grants from the US Army, we are developing a line of wound dressings that will create a new standard for the treatment of traumatic hemorrhage—the leading cause of combat mortality. Currently our line of hemorrhage control products include: XSTAT, XGAUZE, AIRWRAP, SHARKBITE kit and TX2/TX3 Tourniquet Belts.

Rewire AI is a computer vision and machine learning company that specializes in biomedical imaging services, offering a cloud-based artificial intelligence inference engine for clinical and research applications.

At the heart of every great company, you will find an idea that spawned a product, a product that fostered a culture, and a culture that created a brand. A brand that stands uniquely alone in a crowded marketplace. SAM Medical is no exception. What began as a spark of innovation, when founder Dr. Sam Scheinberg saw a groundbreaking medical innovation in a simple gum wrapper, is now a globally recognized brand of emergency medical solutions. Military, law enforcement, fire & rescue, hospital staff–if someone is in the hurt business, odds are they know and trust SAM Medical. To serve these diverse customers and fuel our founder's passion for innovation, SAM has built a world-class organization. Based just outside of Portland, Oregon–a bioscience and technology hub–our Tualatin facilities provide access to best-in-class talent and resources. Our corporate offices, research and development lab, manufacturing facilities and warehouses are aligned and integrated to increase the pace of innovation and get our solutions to our customers quickly. In just 35 years we've managed to place our name alongside the most respected, award-winning, medical giants while maintaining the spirit of innovation celebrated in vertically integrated, agile start-up organizations.

Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and based in Portland Oregon. Our commitment is to become a leader in three areas intended to advance global access to care as reflected by our: (1) expertise in rapid point of care diagnostic assays, especially alternative fluid (e.g. oral, urine, etc) assays, (2) scientific and market leadership in novel HIV epidemiological disease incidence assays and other public health tools and (3) novel clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of researchers, scientists and business people that share our common mission and develops, manufactures and licenses these technology and products to improve access to medical care around the world.

At Serán, Our mission is to provide optimized drug development and manufacturing services for our clients, from discovery to the clinic. Our science-driven approach utilizes predictive design tools, novel chemistry, analytical tools, enabling delivery technologies, and a thorough knowledge of quality and regulatory requirements to guide our customers on their clinical development path. Serán's team are experts in delivery of poorly soluble compounds. Serán employs a range of novel technologies and pharmaceutical manufacturing operations to overcome drug development challenges for both small and large molecules, including complex granulations, spray-dried dispersions, hot melt extrudates, IR and MR tablet technologies, multiparticulates, and engineered particles inhalation. Our custom-built spray driers enable a wide variety of particle formation, from nano-structures to micro-particulates. Our particle engineering approaches are combined with our broad expertise in solid dosage forms resulting in the optimum clinical trial materials for your drug, including suspensions, capsules, and tablets.

Sirona Dx is a technical CRO, providing advanced, high complexity, single cell, multi omics services to accelerate the pace of immunotherapy and targeted therapy development. In contrast to most CROs, we embrace leading edge technologies at an earlier stage, often assisting life science companies with product development. Bridging the silos between tools developers and biopharma means our clients access enabling technologies and expertise sooner and within a CLIA accredited, GCLP laboratory that supports pharma regulatory requirements. Our team can assist with platform selection and with the design, optimization and validation of complex multi-analyte assays. Harness breakthrough technologies to profile and integrate biology with single-cell resolution including tissue spatial context to reveal the next generation of precision biomarker signatures to accelerate therapies towards regulatory approval. Recognized as the original pioneers of spatial biology we launched the first spatial-omics CRO service in 2018 utilizing IMC technology developed by Fluidigm. Today our technology agnostic, spatial biology suite includes all of the leading multiplexed imaging platforms. Our team can develop panels of up to 40 markers to reveal the complex interplay between the immune system and the tumor/tissue microenvironment. We leverage CyTOF technology from Fluidigm to perform ultradeep immune profiling of whole blood and PBMCs with highly multiplexed assays of 40+ markers. High performance RNA extraction methodologies coupled with a comprehensive menu of high parameter IO expression profiling assays supports exploration of complex tumor immunobiology from challenging sample types. From exploratory testing and biomarker development through to clinical trials support, we partner with you every step of the way. Contact us with your specific requirements and our team will guide you to the optimal assays and platforms to support your study.

Sonivate Medical develops and manufactures technologies to reduce healthcare costs and expand access to diagnostic imaging.

Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.

Used by professionals, Tec Labs offers trusted itch relief solutions for poison ivy and oak, head lice treatment and biting insects.

Trace Biosciences is creating imaging agents for surgery. Our mission is to revolutionize surgery by highlighting detailed anatomy in real-time. Our first product is a nerve targeting imaging agent that will prevent surgical nerve damage. Nerve injury is a feared surgical complication affecting 25 million patients annually and incurring undue pain, loss of function, and high cost for follow on treatment and pain management. Currently, surgeons are entirely unassisted in nerve identification and preservation, relying solely on naked eye visualization or anatomical knowledge. If we can successfully develop this, our imaging agents will be used in almost all operating theaters, enable true precision surgery, and vastly improve patient outcomes. We are well funded through non-dilutive grants (SBIR, STTR + regional government) as well as venture capital investments. Founded in 2019 we are now developing our first products that will enter clinical trials in 2023.

Tricol Biomedical, Inc. is a medical device company based in Portland, Oregon, established in 2001. Originally known as HemCon, the company has become a leader in advanced acute wound care and hemostatic solutions. Tricol Biomedical is committed to improving hemostatic and wound care management through innovative products and technologies, with a mission centered on saving lives. The company offers a variety of hemostatic solutions, including its proprietary Chitosan products like HemCon PRO, which are designed for rapid hemorrhage control. Their product range includes items for trauma management, procedural care, and consumer self-care, catering to the needs of healthcare professionals, military personnel, and individuals seeking effective wound care solutions. Tricol Biomedical continues to focus on enhancing care standards in the medical field.

UbiVac is a clinical stage biotech engaged in research and development, and manufacture, of therapeutic immune activators, vaccines and cellular immunotherapies to combat cancer. Used in combination with other immunotherapies, UbiVac’s patented technologies have proven highly effective at improving survival and apparent cure in difficult to treat animal cancers (PMID: 27874054; PMID: 31747946; PMID: 22068657). UbiVac believes that the explanation for this effectiveness lies in several high impact publications from 2021 identifying a previously unknown class of shared non-mutated cancer neoantigens that make up as much as 25% of the antigens on cancer cells (PMID: 33740418; PMID: 33691108; PMID: 34663921). As the non-mutated shared cancer neoantigens are short-lived proteins, the majority are expected to be contained in UbiVac’s DPV-001. Importantly, these findings help explain why UbiVac’s immunotherapy provided cross-protective cancer immunity in preclinical models, something that had not been observed in 50 years of study (PMID: 21810919). These remarkable studies raised the possibility of off-the-shelf Universal Cancer Vaccines (PMID: 33852826). UbiVac has completed an NCI-funded phase I/II adjuvant trial of its lead agent, DPV-001. This trial met its endpoints, determined safety, identified drug formulation, and demonstrated proof-of-concept. Based on these data UbiVac partnered with the Providence Cancer Institute and Incyte on a first-in-human immunotherapy trial of UbiVac’s DPV-001, anti-GITR and anti-PD-1 for advanced HNSCC. The first patients were treated in Q4 2021, and preliminary immunological monitoring data will be presented at AACR in April 2022. UbiVac also has a pipeline of cellular therapies under development. Given that UbiVac’s CEO and CSO, together, have 55+ years of experience with preclinical and clinical studies of adoptive immunotherapy, UbiVac is well positioned to bring their innovative cellular therapy platforms to the clinic.